Dusseldorf - Delayed Quote EUR
Protalix BioTherapeutics Inc (PBDA.DU)
2.6200
+0.1800
+(7.38%)
At close: April 30 at 4:00:08 PM GMT+2
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
53,399
53,399
65,494
47,638
38,350
Cost of Revenue
24,319
24,319
22,982
19,592
16,349
Gross Profit
29,080
29,080
42,512
28,046
22,001
Operating Expense
25,163
25,163
32,052
41,060
42,463
Operating Income
3,917
3,917
10,460
-13,014
-20,462
Net Non Operating Interest Income Expense
237
237
-1,894
-1,383
-7,120
Pretax Income
4,154
4,154
8,566
-14,397
-27,582
Tax Provision
1,222
1,222
254
530
--
Net Income Common Stockholders
2,932
2,932
8,312
-14,927
-27,582
Diluted NI Available to Com Stockholders
2,932
2,932
8,312
-14,927
-27,582
Basic EPS
-0.15
0.04
0.12
-0.31
-0.62
Diluted EPS
-0.15
0.04
0.09
-0.31
-0.62
Basic Average Shares
73,129.7160
72,530.6980
67,512.5270
48,472.1590
44,140.2330
Diluted Average Shares
76,619.6240
81,057.1760
82,424.0160
48,472.1590
44,140.2330
Total Operating Income as Reported
3,917
3,917
10,460
-13,014
-20,462
Total Expenses
49,482
49,482
55,034
60,652
58,812
Net Income from Continuing & Discontinued Operation
2,932
2,932
8,312
-14,927
-27,582
Normalized Income
2,932
2,932
8,312
-14,927
-27,582
Interest Income
1,299
1,299
1,286
1,146
401
Interest Expense
1,062
1,062
3,180
2,529
7,521
Net Interest Income
237
237
-1,894
-1,383
-7,120
EBIT
5,216
5,216
11,746
-11,868
-20,061
EBITDA
6,520
6,520
12,937
-10,782
-18,943
Reconciled Cost of Revenue
24,319
24,319
22,982
19,592
16,349
Reconciled Depreciation
1,304
1,304
1,191
1,086
1,118
Net Income from Continuing Operation Net Minority Interest
2,932
2,932
8,312
-14,927
-27,582
Normalized EBITDA
6,520
6,520
12,937
-10,782
-18,943
Tax Rate for Calcs
0.0003
0.0003
0
0
--
12/31/2021 - 12/14/2009
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade